Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy

Michelle L. Hastings1,*, Joel Berniac2, Ying Hsiu Liu3, Paul Abato2, Francine M. Jodelka1, Lea Barthel1, Sujatha Kumar2, Caroline Dudley2, Mark Nelson2, Kelley Larson2, Jason Edmonds2, Todd Bowser2, Michael Draper2, Paul Higgins2,*, and Adrian R. Krainer3,*

1Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60044, USA
2Paratek Pharmaceuticals Inc., 75 Kneeland Street, Boston, MA 02111, USA
3Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA

Abstract
There is at present no cure or effective therapy for spinal muscular atrophy (SMA), a neurodegenerative disease that is the leading genetic cause of infant mortality. SMA usually results from loss of the SMN1 (survival of motor neuron 1) gene, which leads to selective motor neuron degeneration. SMN2 is nearly identical to SMN1 but has a nucleotide replacement that causes exon 7 skipping, resulting in a truncated, unstable version of the SMA protein. SMN2 is present in all SMA patients, and correcting SMN2 splicing is a promising approach for SMA therapy. We identified a tetracycline-like compound, PTK-SMA1, which stimulates exon 7 splicing and increases SMN protein levels in vitro and in vivo in mice. Unlike previously identified molecules that stimulate SMN production via SMN2 promoter activation or undefined mechanisms, PTK-SMA1 is a unique therapeutic candidate in that it acts by directly stimulating splicing of exon 7. Synthetic small-molecule compounds such as PTK-SMA1 offer an alternative to antisense oligonucleotide therapies that are being developed as therapeutics for a number of disease-associated splicing defects.

INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal-recessive disease caused by homozygous point mutations or deletions in the SMN1 (survival of motor neuron 1) gene (1). The reduction in functional SMN protein resulting from SMN1 mutations leads to the selective degeneration of the lower motor neurons in the ventral horn of the spinal cord, causing progressive muscle weakness and atrophy. SMA affects 1 in ~6000 live births and is the leading genetic cause of infant mortality. Most children with the most severe form of the disease, which accounts for 50 to 60% of affected individuals, die before the age of 2 years in the absence of supportive respiratory care (2). There is no cure for SMA at present.
SMN1 encodes SMN protein, which is part of a molecular complex essential for the assembly of small nuclear ribonucleoprotein particles (snRNPs) (3,4). snRNPs are integral components of the spliceosome, a large multiprotein-RNA complex that processes precursor messenger RNA (pre-mRNA) transcripts into mature mRNA by splicing out intronic sequences (5). Splicing is a required step in gene expression, and the loss of a key component of the pathway would be expected to be incompatible with life. However, the homozygous loss of SMN1 is partially compensated for by the presence of a second gene, SMN2, which also codes for SMN protein. SMN2 cannot fully compensate for the loss of SMN1 in SMA because the expression of full-length protein generated from SMN2 is substantially lower than that from SMN1. This difference is due to a single nucleotide change in SMN2 exon 7 relative to SMN1. This nucleotide difference, although resulting in a synonymous codon, causes exon 7 to be excluded from most of the mRNA expressed from the SMN2 gene (6,7). This Δ7 mRNA codes for a truncated protein that is highly unstable. A small percentage of SMN2 spliced transcripts retains exon 7 and codes for full-length, functional SMN protein. Disease severity in SMA correlates inversely with SMN2 gene copy number (8) and SMN protein abundance (9,10).

SMA is likely caused by insufficient SMN protein in affected tissues, although it is not clear why spinal cord motor neurons are especially vulnerable. Thus, increasing functional SMN protein production from SMN2 is expected to have therapeutic value for SMA. One promising approach to achieve this goal is to improve the efficiency of SMN2 exon 7 splicing.

The pre-mRNA splicing machinery, especially factors involved in alternative splicing, is a viable target for altering gene expression as a treatment for human diseases (11–13). Pre-mRNA splicing catalyzed by the spliceosome is a two-step reaction (5,14). The spliceosome is a complex machine composed of ~200 protein components and five small nuclear RNAs (snRNAs) (15). The role of each individual factor in splicing is largely unknown, although it is clear that interactions of various factors with cis-acting pre-mRNA sequences contribute to alternative splice-site selection.

Methods for targeting cis-acting sequence elements to therapeutically alter splicing patterns are becoming more common, although targeting of trans-acting splicing factors is relatively undeveloped. Small molecules make up the majority of traditional therapeutics in part because they can be modified and designed to increase potency, efficacy, and bioavailability. In the case of SMA, an ideal drug would have the ability to cross the blood-brain barrier and target spinal motor neurons, the cells that are affected by the disease. Several compounds have been found to increase full-length SMN protein production. However, their activities are largely nonspecific, likely eliciting widespread changes in transcription, localization, or phosphorylation of splicing factors as well as unrelated components (16). In addition, a number of compounds, such as aclacinomycin, are toxic to cells (17,18). Drugs that target specific splicing factors may be less toxic and more potent than nonspecific compounds.

Tetracyclines, a widely used drug class of demonstrated safety, bind to specific RNAs and proteins and modify their structure and function (19,20). Moreover, small-molecule drugs, including aclacinomycin, have been shown to increase full-length SMN2 mRNA and protein in cell culture (17). The structural similarity between tetracyclines and aclacinomycin suggested that the former might represent a nontoxic means of altering the splicing event. We present here the characterization of a tetracycline-like molecule, discovered as a result of screening a diverse collection of tetracycline derivatives. PTK-SMA1 represents a new class of compounds that may be useful for the treatment of SMA.
RESULTS

Identification of a small-molecule activator of SMN2 exon 7 splicing

To identify compounds that specifically target the splicing machinery to increase the extent of SMN2 exon 7 splicing, we used a cell-free splicing system and tested a number of small molecules that had been reported to increase SMN protein concentration in cells. A cell-free splicing assay has an advantage over cell-based assays in that it allows the identification of compounds that directly alter the splicing reaction in the absence of other steps in gene expression, such as transcription, 3′-end processing, mRNA export, and translation; in addition, any effects on the turnover of precursor or product RNAs can be simultaneously assessed. For the cell-free assay, SMN2 pre-mRNA transcribed in vitro from an SMN2 minigene comprising exon 6, exon 7, the 5′ portion of exon 8, and the intervening introns was used as a substrate to assess exon 7 splicing in HeLa cell nuclear extract, with an antisense peptide nucleic acid (PNA) as a positive control (21).

Indoprofen, valproic acid, and salbutamol, all compounds that increase full-length SMN protein and/or mRNA concentration in cells (16,22–24), did not affect splicing activity in the cell-free splicing assays (Fig. 1). Kinetin, a compound that has been shown to increase exon inclusion in IKBKAP and a number of other gene transcripts in cells (25), also did not significantly improve exon 7 inclusion. The results with aclarubicin were particularly interesting because this compound has been reported to increase the proportion of transcripts including exon 7 relative to those lacking exon 7 in cells (17), yet it had no effect on exon 7 splicing in our cell-free assay. Because aclarubicin is structurally similar to tetracycline, we also screened a number of tetracycline derivatives from Paratek Pharmaceuticals’ chemical library (26). One of these derivatives, PTK-SMA1, increased the amount of full-length SMN2 transcripts relative to the exon 7–skipped form (Fig. 1). The effect of PTK-SMA1 was dose dependent, with the highest concentration of exon 7 splicing observed at 10 μM.

PTK-SMA1 is a novel compound generated by derivatization of the tetracycline scaffold at the C7 position of the naphthacene ring (26) (Fig. 2A). The position 7 substitution is critical for PTK-SMA1 activity in splicing. Compounds that are structurally related to PTK-SMA1 but lacking the position 7 substitution, such as doxycycline and minocycline, had no effect on exon 7 splicing (Fig. 2). Doses of PTK-SMA1 higher than 40 μM consistently showed a general inhibition of SMN2 splicing (Fig. 2C). Overall, at its maximum active concentration, PTK-SMA1 elicited a fourfold increase in the percent of SMN2 transcripts that included exon 7. Moreover, PTK-SMA1 improved SMN2 exon 7 splicing 30% above that of the SMN1 control (Fig. 2D). Together, these results demonstrate that the tetracycline derivative PTK-SMA1 is a highly effective activator of SMN2 exon 7 splicing.

PTK-SMA1 specifically promotes exon 7 inclusion

To determine whether the activity of PTK-SMA1 is specific to SMN2 exon 7 splicing, we tested its effect on the splicing of additional substrates with the cell-free assay. SMN1 exon 7 splicing was stimulated to some degree by PTK-SMA1 (Fig. 3). A BRCA1 minigene transcript with a G to T point mutation in exon 18 (E1694X) that results in skipping of the exon (27) was also tested. This mutation is similar to the C to T change in SMN2 exon 7 relative to SMN1: both the BRCA1 E1694X mutation and the SMN2 change are at position 6 of the affected exon and both disrupt an SF2/ASF exonic splicing enhancer (ESE) motif (21,28). However, when PTK-SMA1 was included in the BRCA1 pre-mRNA splicing reaction, only a subtle change in exon 18 splicing was observed (Fig. 3). PTK-SMA1 similarly did not substantially enhance constitutive splicing of β-globin or immunoglobulin M (IgM) M1–M2 splicing substrates (Fig. 3). Alternative splicing of a model substrate with two competing 5′ splice sites (5′Dup) also was not affected by PTK-SMA1. Thus, PTK-SMA1 does not appear to be a general activator...
of splicing. Instead, the molecule acts in a specific manner to stimulate SMN2 exon 7 splicing, and not other splicing events, at least for the substrates we have tested to date.

PTK-SMA1 may stimulate splicing of SMN2 exon 7 either by promoting intron 6 or intron 7 removal or by blocking splicing from exon 6 to exon 8. To distinguish among these possibilities, RNA transcripts were made from minigenes comprising exon 6, intron 6, and exon 7 (SMN67) or exon 7, intron 7, and exon 8 (SMN78) of the SMN2 gene, and splicing was tested in the cell-free assay in the presence or absence of PTK-SMA1. Treatment resulted in a modest stimulation of exon 6 to exon 7 splicing, peaking at 2.5 to 5 μM (Fig. 4, A and D). Exon 7 to exon 8 splicing was not stimulated by PTK-SMA1 and, in fact, a modest reduction in spliced product relative to unspliced transcript was observed (Fig. 4, B and D). This reduction reflects, at least in part, stabilization of unspliced pre-mRNA without further conversion of precursor into spliced products. These results suggest that PTK-SMA1 may act by shifting the balance of splicing paths through selective inhibition of specific splicing events that are normally competing. This idea is supported by results from splicing of an RNA transcript equivalent to SMN2 with exons 6, 7, and 8, except that the 5′ splice site following exon 7 was mutated, such that the only expected splicing event is from exon 6 to exon 8 (SMN2Δex7-5′ss). This splicing event was inhibited at a concentration of 5 μM PTK-SMA1 (Fig. 4, C and D). Together, these results suggest that PTK-SMA1 exerts its pronounced effect on exon 7 splicing by stimulating splicing from exon 6 to exon 7 while also inhibiting exon 7 skipping.

### PTK-SMA1 increases SMN protein concentrations in SMA patient fibroblasts

To have therapeutic value, an increase in SMN2 exon 7 splicing must ultimately result in an increase in full-length SMN protein concentration. To test whether PTK-SMA1 can elevate SMN protein abundance, we cultured fibroblast cells derived from an SMA patient in the presence of the compound. Reverse transcription polymerase chain reaction (RT-PCR) analysis of SMN2 exon 7 splicing from the treated and untreated cells confirmed a dose-dependent increase in exon 7 splicing (Fig. 5A). Western blot analysis of total cellular proteins from treated and untreated cells also revealed a significant increase in SMN protein in cells treated with PTK-SMA1. A ~40% increase in the amount of SMN protein was observed in cells treated with 10 μM PTK-SMA1 relative to vehicle-treated control cells (Fig. 5B). SMN protein localizes to Cajal bodies or gems, which are observed as distinct foci in normal cells (29,30). In SMA patient cells, however, a dramatic reduction in SMN-containing gems is typically observed (9,10) (Fig. 5C). PTK-SMA1 treatment of cells for 48 hours led to an increase in SMN-containing gems. PTK-SMA1 was more potent than valproic acid (Fig. 5C) (31), a compound that is known to elevate SMN protein, and is now in clinical trials for SMA therapy (23,31,32). The maximum number of gems was observed upon treatment of cells with 2.5 μM PTK-SMA1.

### PTK-SMA1 increases SMN2 exon 7 splicing and SMN protein concentration in mice

To determine whether PTK-SMA1 can increase SMN2 exon 7 splicing and SMN protein concentration in vivo, we tested PTK-SMA1 activity in a mouse model of SMA. These mice have a homozygous deletion of the single mouse Smn gene and have four copies of a human SMN2 transgene (33). The mice have short tails and small ears, typical of a mild type III–like SMA phenotype in mice (34). Mice were treated by daily intraperitoneal injection of PTK-SMA1 (25 or 50 mg/kg) over the course of 6 days. Because of the mild phenotype and normal life span of these SMA mice, phenotypic rescue by PTK-SMA1 could not be evaluated; however, we chose this strain so that mRNA splicing and protein expression from the transgene could be measured in adult mice. Two hours after the final PTK-SMA1 dosing, RNA was isolated from the liver tissue and semiquantitative radioactive RT-PCR analysis was performed to detect changes in SMN2 exon 7 splicing. A factor of 1.5 increase in exon 7 inclusion was observed in the PTK-SMA1–treated mice (Fig. 6A). Quantitative Western blot analysis of
protein lysates from the liver of treated and untreated mice showed an increase by a factor of >5 in SMN protein concentration in PTK-SMA1–treated mice (Fig. 6B). SMN protein abundance in the liver of SMA mice was ~10% of that in normal mice. Thus, treatment with PTK-SMA1 increased the amount of SMN protein to ~50% of the concentration found in wild-type mice.

Similar results were obtained with a different mouse model of type I SMA that has two copies of a human SMN2 transgene (Fig. 6, C and D) (7). Adult transgenic mice with one or both copies of the wild-type mouse Smn gene were treated by daily intraperitoneal or intravenous injection of PTK-SMA1 over the course of 4 days. RNA and protein from the liver of treated animals were analyzed by RT-PCR and Western blotting with human-specific primers and antibody, respectively. A factor of 1.4 increase in exon 7 inclusion was seen in the intraperitoneally treated mice (Fig. 6C). This increase in exon 7 splicing corresponded with a nearly twofold increase in SMN protein concentration (Fig. 6D). This effect on SMN protein was lower than the effect we observed with the Smn−/− type III SMA mice. This difference likely reflects the longer duration of treatment and higher dosing in those mice. Type I SMA mice treated by intravenous injection of PTK-SMA showed smaller increases in full-length mRNA and protein expression compared to intraperitoneal administration (Fig. 6, C and D).

**DISCUSSION**

SMA is caused by loss of the SMN1 gene, which results in reduced cellular concentration of full-length SMN protein, expressed from the paralogous gene SMN2. One promising strategy for SMA therapy is to increase SMN protein abundance or function in SMA patients. A logical approach to achieve this goal is to improve the efficiency of splicing of exon 7 from SMN2 and thereby increase full-length SMN2 mRNA and protein concentration expressed from the gene. To this end, we performed a directed screening of small-molecule compounds for their ability to improve SMN2 exon 7 splicing in a cell-free splicing assay. We identified a novel small-molecule compound, PTK-SMA1, which increases SMN2 exon 7 splicing and SMN protein concentrations in vitro and in vivo. To our knowledge, this compound is the only molecule identified to date that has been demonstrated to alter splicing by directly targeting the splicing reaction to promote a specific splicing pathway.

The degree to which SMN2 mRNA and SMN protein concentrations must increase to achieve a therapeutically valuable effect is not clear. SMA carriers who only have one functional copy of SMN1 are asymptomatic. Individuals with homozygous deletions of SMN1 but multiple copies of SMN2 have complete protection from the disease or are less severely affected (8, 35–37). These studies suggest that increasing SMN2 expression by a factor of 2 could be clinically beneficial. In the cell-free assay, PTK-SMA1 improved splicing of exon 7 in SMN2 pre-mRNA to a concentration exceeding that seen with SMN1 pre-mRNA, suggesting that the molecule has the potential to completely rescue the splicing defect in SMN2. PTK-SMA1 administration to type III SMA mice resulted in a 50% increase in SMN2 exon 7 inclusion in the liver, which translated into a nearly fivefold increase in SMN protein concentrations compared to untreated animals. The fact that a modest increase in SMN2 exon 7 splicing results in a dramatic increase in SMN protein concentrations suggests additional levels of regulation in SMN gene expression and highlights the value of targeting the splicing reaction for SMA therapy. Although these results indicate that PTK-SMA1 is a promising SMA therapeutic candidate, the activity of this molecule in motor neurons must still be determined.

PTK-SMA1 is a tetracycline derivative that has been modified at the C7 position of the tetracycline backbone. Tetracyclines are anthracycline-type antibiotics that inhibit binding of bacterial transfer RNA to ribosomes (38). These molecules are safe, well-characterized, and commonly used antibacterial drugs in humans. PTK-SMA1 has reduced antibacterial activity.
and phototoxicity relative to other tetracycline-derived molecules, such as doxycycline and minocycline, and these characteristics may improve its tolerability in humans.

The fact that PTK-SMA1 promotes SMN2 exon 7 splicing in our cell-free splicing assay indicates that the compound is targeting the splicing reaction directly to improve exon 7 inclusion. Tetracyclines in general can bind RNA and affect RNA structure, synthesis, and stability (19,20). Tetracyclines are also able to bind and activate proteins, such as the tetracycline repressor (39). The mechanism by which PTK-SMA1 stimulates SMN2 exon 7 splicing could be by direct binding to the SMN2 pre-mRNA or an RNA component of the splicing machinery (such as a U snRNA) or it could bind to a protein involved in splicing. It is possible that PTK-SMA1 could alter structure or activity in either of these scenarios. It is also possible that the tetracycline backbone binds to RNA nonspecifically and the PTK-SMA1–specific side chain contributes binding specificity or a protein interaction that alters splicing. Support for this idea comes from studies that have shown that tetracycline and other antibiotics can inhibit splicing at very high (>100 μM) concentrations (40). Indeed, PTK-SMA1 appears to function in such a way as to stimulate a particular splicing reaction in a specific manner at lower concentrations and to nonspecifically inhibit splicing at higher concentrations.

One speculative idea for the mechanism of action of PTK-SMA1 is that it is fortuitously acting as part of a riboswitch to control exon 7 splicing. Riboswitches are structured RNA sequences within a transcript that change structure after the binding of a regulatory molecule. This change in structure interferes with gene expression, typically by altering transcription, translation, or RNA processing. Natural riboswitches have not yet been identified in mammalian cells. However, they are a common mechanism of gene control in bacteria and have been identified in fungi and plants (41–43). It is intriguing that the thiamin pyrophosphate–responsive riboswitch that has been identified in eukaryotes controls splicing and alternative 3′-end processing of mRNAs (43). This finding indicates that natural riboswitches can regulate RNA splicing. Synthetic riboswitches that are recognized by tetracycline have been engineered in yeast to regulate pre-mRNA splicing (44), demonstrating the ability of the tetracycline compound class to alter splicing through recognition of a specific RNA structure. Indeed, secondary structure is an important splicing-regulatory feature of the SMN1 or SMN2 RNA transcript (45).

The structure of PTK-SMA1 is critical for splicing activity. Aclarubicin, the tetracycline derivative that has activity in cells and provided the impetus for investigating the tetracycline scaffold as a platform for screening SMN2 exon 7 activators, did not improve splicing of exon 7 in the cell-free splicing assay. Aclarubicin is most commonly used as a chemotherapeutic agent for cancer therapy and is extremely cytotoxic (46). It is possible that the effect of aclarubicin on SMN2 splicing and SMN protein concentrations in cells (17) is a secondary effect resulting from global changes in the cell. Nonetheless, when modified with particular side chains, such as that on PTK-SMA1, the tetracycline scaffold forms the basis of a potent activator of SMN2 exon 7 splicing.

SMN2 exon 7 splicing is controlled by a number of cis-acting sequence elements and trans-acting factors. The C residue at position 6 of SMN1 exon 7 is part of an ESE element that is recognized by the serine-arginine-rich (SR) protein SF2/ASF (21). This ESE is critical for recognition and splicing of exon 7. In SMN2 pre-mRNA, position 6 of exon 7 is a U rather than aC. The U changes the ESE such that it is not effectively recognized by SF2/ASF and exon 7 is skipped most of the time. In the absence of the ESE, inhibitory interactions between splicing silencers and heterogeneous nuclear RNP A1 predominate and result in exon skipping (21, 47). Although the single-nucleotide difference between SMN1 and SMN2 is sufficient to prevent efficient SMN2 exon 7 splicing, other cis-acting motifs are involved in splicing of exon 7, including an ESE that is recognized by the Tra2 family of SR-like proteins (6,48–51).
Additional cis-acting elements within the flanking introns and in exon 7 are also important for exon 7 inclusion. Some of these elements are recognized by trans-acting splicing factors and others appear to be regulatory secondary structures (52–54). Binding of splicing factors to the 3′ splice site is also impaired in SMN2 relative to SMN1 (55). Any of the splicing factors or sequence elements that control exon 7 splicing could be a potential target for PTK-SMA1.

A number of molecules have been identified that modulate alternative splicing in general (12), and some have also been identified that increase the concentration of full-length SMN2 mRNA in cells (18,56). However, there is no evidence that these act directly on splicing as opposed to, for example, mRNA stability. We have tested a number of these compounds in the cell-free splicing assay and found that none of them altered splicing of SMN2 exon 7 (Fig. 1). These molecules may influence splicing by modulating transcription, nuclear transport, stability, signaling pathways, or some other cellular process that can affect splicing indirectly. Although kinetin improves exon inclusion of a number of transcripts (25), indicating that the compound may have a general effect on the splicing reaction, it did not significantly affect SMN2 exon 7 splicing in our assay (Fig. 1). Several small molecules that act specifically on components of the splicing machinery have been described. To date, these compounds have all been demonstrated to be inhibitors of splicing (57–61). PTK-SMA1 appears to be unique in its ability to influence splicing directly and promote a specific splicing event.

PTK-SMA1 improves exon 7 splicing in two ways: by stimulating splicing of the intron upstream of exon 7 and by inhibiting splicing from exon 6 to exon 8 (exon 7 skipping) (Fig. 4). It is possible that both of these activities are mediated by a single protein or sequence element. ESEs, for example, which typically function to promote splicing of nearby splice sites, also block skipping of the exon in which they are located (62).

Although the precise molecular target of PTK-SMA1 is not yet known, our screening assay has narrowed the target down to the splicing reaction itself. Discovering the mechanism of action of PTK-SMA1 in splicing is an important goal toward its development as a therapeutic and would also increase our understanding of how splicing can be targeted by small molecules. Because many diseases are caused by defects in RNA splicing (63), the therapeutic impact of this drug class could be significant. Tetracycline may be a chemical scaffold that can be manipulated to generate agents for context-specific repair of aberrant splicing. Of more immediate impact, PTK-SMA1 and its derivatives are promising therapeutic candidates for the treatment of SMA.

A major goal for SMA therapy is the development of a drug that can penetrate the blood-brain barrier and increase SMN protein concentration in the motor neurons to stop or reverse disease progression. PTK-SMA1 does not cross the blood-brain barrier, and hence, we examined its activity in the liver of transgenic mice as a proof of principle for the compound’s ability to promote SMN2 exon 7 splicing in vivo. Ongoing structure-activity relation studies are focused on modifying PTK-SMA1 to produce a molecule that efficiently crosses the blood-brain barrier and improves SMN protein expression in the central nervous system.

**MATERIALS AND METHODS**

**Cell-free splicing**

Plasmids pCI-SMN1 and pCI-SMN2 linearized with Sal I (64) and BRCA1E1694X (28) were used as templates for in vitro transcription with T7 RNA polymerase (Promega) to make SMN1, SMN2, and BRCA1 transcripts. SMN67 and SMN78 were made by RT-PCR using pCI-SMN2 as a template. The forward primer T7SMNex6-5′-TAATACGACTCATATAGGATATTCCCCACCACCTC-3′ or T7SMN2ex7-5′-TAATACGACTCATATAGGTTTTTAGACAAAAATCAAAAAG-3′ includes a 5′ T7 RNA
polymerase promoter sequence and the 5' end of SMN2 exon 6 or exon 7, respectively. Reverse primers were specific to the 3' end of exon 7 with a 5' splice site at the 3' end (SMNexon7L +5'-5'-GGAGACTTTACTCCTTAATTAGGAATGTG-3') or 75 nucleotides of exon 8 with a 5' splice site (SMNex8-75R+5'R-5'.AAGTACTTTACTCCTTAATTAGGAATGTG-3'). SMN2Δex7-5'ss was made by overlap extension PCR using pCI-SMN2 as a template and the primers (SMNex6-5'-ATTCCCCACCACCTC-3' and SMNCL-5'-GCAGACTTACTCCTTAATTTAAGGAATGTG-3').

Cell culture and treatments

SMA type I homozygous and carrier fibroblasts (3813 and 3814, Coriell Cell Repositories) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum. For treatments with compounds, cells were split at a density of 1 x 10^5 to 2 x 10^5 cells per well in six-well plates the day before addition of compounds. Compounds or vehicle control [0.176 mM NaOH or 0.05% (v/v) dimethyl sulfoxide] was added directly to cells, which were then grown for an additional 48 hours. Cells were then washed with 1x phosphate-buffered saline (PBS) and collected by scraping into 1x PBS. After centrifugation, PBS was removed and cells were lysed in Laemmli buffer and heated at 99°C for 10 min.

Western blot analysis

Protein samples were separated by SDS-PAGE and transferred onto Immobilon-P membranes (Millipore). Blots were probed with mouse monoclonal antibodies specific for SMN (BD Biosciences) and mouse monoclonal antibodies specific for human SMN protein or β-actin (Sigma) followed by Alexa Fluor 594-conjugated secondary antibody against mouse IgG (Invitrogen) or horseradish peroxidase (HRP)–conjugated goat secondary antibody against mouse IgG. Detection and quantitation was performed with a Typhoon 9400 Variable Mode Imager (GE Healthcare) and ImageQuant T software for fluorescence-labeled blots or with Lumi-Light Western Blotting Substrate (Roche Diagnostics) for HRP-labeled blots.

Immunofluorescence

Fibroblast cells were plated on coverslips and grown in DMEM for 12 hours and then treated with compound or vehicle control. After 12 hours, the medium was removed and cells were washed with PBS and treated with fresh compound. Cells were treated every 12 hours, and 48 hours after the first treatment, they were washed with PBS and fixed with 4% (v/v) paraformaldehyde in PBS for 10 min. The fixed cells were washed with PBS, permeabilized in 0.2% (v/v) Triton X-100 and 0.5% (w/v) bovine serum albumin (BSA) in PBS for 5 min on ice, blocked for 30 min in blocking buffer [2% (v/v) normal goat serum and 2% (w/v) BSA], and incubated for 1 hour in blocking buffer containing mouse monoclonal antibody against
SMN (Sigma). Cells were washed with PBS and incubated for 1 hour in blocking buffer containing Alexa Fluor 594–conjugated goat secondary antibody against mouse IgG (Invitrogen). Cells were washed with PBS and coverslips were mounted with Prolong Gold mounting solution containing 4′,6-diamidino-2-phenylindole (DAPI) for staining the nucleus (Invitrogen). Cells were analyzed with an Axioplan 2i fluorescence microscope (Carl Zeiss) equipped with Chroma filters (Chroma Technology). OpenLab software (Improvision) was used to collect images from a charge-coupled device camera (Hamamatsu). Cajal bodies or gems were counted by random field selection. Cell number was determined based on the number of DAPI-stained nuclei. At least three fields of view were counted.

**Mice**

Transgenic mice carrying four copies of human SMN2 were homozygous null at the mouse Smn locus (hSMN2+/−; Smn−/−)(33) or had two copies of the transgene and were heterozygous or wild type at the mouse Smn locus (7). Mice were maintained in accordance with the Cold Spring Harbor Laboratory Animal Care and Use regulations.

For experiments with hSMN2+/−; Smn−/− mice (33), PTK-SMA1 was dissolved in 10% (w/v) polyethylene glycol 400 in PBS and given to mice at 25 mg/kg by intraperitoneal injection once per day (25 mg/kg) or twice per day (50 mg/kg). Control animals received equal volumes of vehicle alone. Mice were injected for 6 days and killed 2 hours after the first injection on the final day. Treatment was well tolerated, with the exception of one mouse that died after two injections of PTK-SMA1 (50 mg/kg) and one mouse that died after four injections of PTK-SMA1 (25 mg/kg). These mice were excluded from the analysis. Mouse livers were perfused with ice-cold saline and then snap-frozen in liquid nitrogen and stored at −70°C.

For experiments with hSMN2+/−; Smn+/− or hSMN2+/+; Smn+/+ mice, PTK-SMA1 was dissolved in water and injected into the tail vein or peritoneum once a day for 4 days. Mice injected with PTK-SMA1 (50 mg/kg, intravenously) were injected with 25 mg/kg for the final treatment. One of these mice died after the third treatment. Mice were killed 24 hours after the final injection and tissues were collected and snap-frozen in liquid nitrogen.

RNA was extracted from livers using Trizol reagent (Invitrogen) according to the manufacturer’s protocol. To prepare protein lysates, 100 mg of liver tissue was sonicated in 900 μl of radioimmununoprecipitation assay buffer [1× PBS, 0.25% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM EDTA, and complete mini protease inhibitor cocktail (Roche)].

**RT-PCR**

Human-specific primers for the amplification of human SMN2 transcripts in RNA samples from transgenic mouse liver were E4-33to55-F (5′-AAGTGAGAACTCCAGGTCTCCTG-3′) and E8-15to36-R (5′-GTGGTGTCATTTAGTGCTGCTC-3′). The RT-PCR reactions were performed as previously described (64). PCR products were labeled with [α-32P]2′-deoxycytidine 5′-triphosphate and analyzed by 6% native PAGE followed by phosphorimage analysis.

For analysis of SMN2 exon 7 splicing in 3813 fibroblasts, total RNA was isolated from cells with RNeasy kit (Qiagen) according to the manufacturer’s instructions. The following primers were used to amplify endogenous SMN2 mRNA: SMN2 FwdP (5′-ATAATTCCCCCACCACCCTC-3′) and SMN2 RevP (5′-GCCTACCCACCCTGCTTG-3′). The PCR cycling conditions were set as follows: 95°C for 5 min, 23 cycles of 1 min at 95°C, 2 min at 55°C, 3 min at 72°C, and a final extension time of 10 min at 72°C. PCR products were resolved by electrophoresis through 2% agarose gels and visualized by ethidium bromide.
staining (Invitrogen). The band intensities were quantitated with ImageJ and AlphaImager 2200 version 5.5 software.

**Statistical analysis**

The data are presented as the mean and error bars represent the SEM. Data points were compared by the two-tailed t test, and the P values and number of independent experiments are indicated in the figures and/or legends.

**Acknowledgments**

We thank A. Burghes, E. Androphy, L. Simard, and K. Sahashi for invaluable advice; J. Jarecki and X. Roca for helpful discussions, advice, and comments on the manuscript; Y. Hua for the human-specific SMN antibody and critical comments on the manuscript; and Y. Dai for advice on statistical analysis.

**Funding:** Families of SMA research awards to M.L.H., A.R.K., and Paratek Pharmaceuticals and NIH grants 1U01NS061801 (P.H.) and GM42699 (A.R.K.).

**REFERENCES AND NOTES**


Sci Transl Med. Author manuscript; available in PMC 2010 May 4.


Fig. 1.
Identification of compounds that increase SMN2 exon 7 splicing in vitro. (A) Schematic of the 3’ region of the SMN1 and SMN2 genes. SMN1 has a C at position 6 of exon 7 and SMN2 has a T. Hatched lines depict predominant splicing pathway for the respective gene transcripts. (B) Cell-free splicing analysis of SMN2 minigene transcript in HeLa cell nuclear extract in the presence of PTK-SMA1 (2.5, 5, and 10 μM), aclarubicin (Acla) (40 and 80 μM), and indoprofen (Ind) (20 and 40 μM). Lane 1, addition of vehicle only; lane 2, positive control with an antisense PNA peptide that promotes exon 7 inclusion (65). (C) Quantitation of SMN2 exon 7 splicing in vitro. Bars indicate the % exon 7 inclusion [(included / (included + skipped) × 100). Triangles indicate increasing concentrations of compounds: PTK-SMA1 (5 and 10 μM), aclarubicin (40 and 80 μM), valproic acid (VPA) (20 and 40 μM), kinetin (5 and 10 μM), and salbutamol (Sal) (5 and 10 μM). Error bars represent SEM (n = 3). **P < 0.005, t test.
Fig. 2. The tetracycline derivative PTK-SMA1 promotes \(SMN2\) exon 7 inclusion. (A) Chemical structures of PTK-SMA1, minocycline, and doxycycline. (B) Quantitation of \(SMN2\) exon 7 in vitro splicing in untreated reactions or reactions incubated with PTK-SMA1 (\(n = 4\)), minocycline (\(n = 3\)), or doxycycline (\(n = 4\)) at each of the indicated final concentrations. Results are plotted as the % exon 7 inclusion, as in Fig. 1C. Error bars represent SEM. \(* * * P < 0.005, \* * P < 0.0005\) relative to untreated, \(t\) test. (C) \(SMN\) exon 7 splicing in vitro. \(SMN2\) was incubated in the absence (−) or presence of increasing amounts of PTK-SMA1 (lanes 5 to 13: 0.625, 1.25, 2.5, 5, 10, 20, 40, 80, and 160 \(\mu\)M, respectively). PNA indicates the addition of SMN-RS10 PNA peptide (65). \(SMN1\) pre-mRNA was spliced in lanes 1 and 2 as a control. (D) Quantitation of in vitro splicing of \(SMN1\) and \(SMN2\) exon 7 splicing and the stimulation of \(SMN2\) exon 7 by PTK-SMA1 at peak activity. Error bars represent SEM (\(n = 380\)). \(* * * P < 0.0005\) relative to untreated.
PTK-SMA1 acts specifically on SMN2 exon 7 splicing. (A) The effect of PTK-SMA1 on splicing in vitro. Splicing reactions with the indicated pre-mRNA substrates were incubated without PTK-SMA1 (lanes 1, 4, 8, 11, and 14) or with 5 μM PTK-SMA1 (lanes 2, 6, 9, 12, and 15) or 10 μM PTK-SMA1 (lanes 3, 7, 10, 13, and 16). PNA peptide was used as a positive control for splice-site switching (lane 5) and, in this case, refers to a PNA sequence targeted to the BRCA1 transcript, as previously described (65). Unspliced (un) and spliced (sp) products are indicated. inc and skip refer to spliced products that include or skip exon 18, and prox and dist refer to splicing to proximal or distal alternative 5′ splice sites. (B) Quantification of in vitro splicing. Splicing was calculated as either included / (included + skipped) × 100 (for
SMN1 and BRCA1E1694X) or spliced / (unspliced + spliced) × 100 (for 5’Dup, IgM, and β-globin) and then normalized to the value for the corresponding untreated control. SMN2 values are included for comparison and are identical to Fig. 1. Error bars represent SEM (n = 3).
Fig. 4.
PTK-SMA1 stimulates exon 6 to exon 7 splicing and blocks exon 7 skipping. (A) In vitro splicing analysis of SMN2 intron 6. PTK-SMA1 was included in the reactions at final concentrations of 1.25, 2.5, 5, 10, 20, and 40 μM (lanes 2 to 7, respectively). Arrowhead indicates the released intron lariat. (B) Splicing of SMN2 intron 7. PTK-SMA1 was included in the reactions at increasing doses of 1.25, 2.5, 5, 10, and 20 μM (lanes 2 to 6, respectively). (C) SMN2 exon 7 skipping with the SMN2Δex7-5′ss transcript. PTK-SMA1 was included in the reaction at final concentrations of 2.5, 5, 10, 20, 40, and 80 μM (lanes 2 to 7, respectively). Unspliced pre-mRNA transcripts and spliced products are indicated to the right of each gel. (D) Quantitation of splicing from in vitro reactions like those in (A) to (C). Average values are
graphed from SMN67 (n = 7; except 2.5 and 40 μM, n = 6), SMN78 (n = 3; except 2.5 and 40 μM, n = 2), and SMN2Δex7-5’ss (n = 2). Error bars represent SEM.
Fig. 5.
PTK-SMA1 increases SMN protein concentration in SMA patient fibroblast cells. Cells were treated with the indicated concentrations of PTK-SMA1. Total protein or RNA was collected after 48 hours. (A) RNA was analyzed by RT-PCR and SMN2 spliced products were separated on a 2% agarose gel. A representative gel is shown. The graph represents the mean % of exon 7 splicing [(included / (included + skipped) × 100] normalized to untreated cells in a series of independent experiments. Error bars show SEM. **P < 0.005. (B) Western blotting with SMN and β-actin antibodies. The plotted data represent the mean change in SMN relative to β-actin protein concentrations in drug-treated cells relative to untreated cells. Error bars represent SEM (n = 5). *P < 0.05, **P < 0.001 relative to control, t test. (C) Gems or Cajal bodies were detected by immunofluorescence microscopy with an SMN antibody. A number of gems were quantitated in untreated 3814 control cells or in 3813 cells treated with the indicated concentrations of PTK-SMA1 or valproic acid. The graph plots the number of gems per 100 cells. Each circle represents an independent experiment and the bar indicates the average of all measurements.
Fig. 6. PTK-SMA1 increases SMN2 exon 7 splicing and SMN protein concentration in SMA mice. (A) RT-PCR analysis of RNA from liver of type III SMA adult mice (hSMN2+/+; Smn−/−) treated with PTK-SMA1 or vehicle control. Transcripts including and skipping human SMN2 exon 7 are labeled. The plotted data represent the mean % exon 7 inclusion in PTK-SMA1-treated and control mice. Error bars represent the SEM, with n displayed above the respective bars. (B) Western blot analysis of protein lysates from liver isolated from mice treated with PTK-SMA1. β-Actin was used as a loading control. Mean SMN to β-actin ratios are shown graphically. Error bars represent the SEM. (C) RT-PCR analysis of RNA from liver of transgenic SMA adult mice (hSMN2+/+; Smn+/+ or hSMN2+/+; Smn+/−) treated with PTK-SMA1 by intravenous (iv) or intraperitoneal (ip) injection. Representative samples are shown. The graph represents the mean % exon 7 inclusion in PTK-SMA1–treated and control mice. Error bars represent SEM, with n displayed above the respective bars. (D) Western blot analysis of liver protein lysates probed with a human-specific SMN antibody. β-Actin was used as a loading control. Mean SMN to β-actin ratios normalized to untreated samples are shown graphically. Error bars represent the SEM of values from samples shown in blots.